<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="publisher-id">JCBN</journal-id><journal-title-group><journal-title>Journal of Clinical Biochemistry and Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0912-0009</issn><issn pub-type="epub">1880-5086</issn><publisher><publisher-name>the Society for Free Radical Research Japan</publisher-name><publisher-loc>Kyoto, Japan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25120277</article-id><article-id pub-id-type="pmc">4078065</article-id><article-id pub-id-type="publisher-id">jcbn13-76</article-id><article-id pub-id-type="doi">10.3164/jcbn.13-76</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Citrulline increases cholesterol efflux from macrophages <italic>in vitro</italic> and <italic>ex vivo</italic> via ATP-binding cassette transporters</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Uto-Kondo</surname><given-names>Harumi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ayaori</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nakaya</surname><given-names>Kazuhiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Takiguchi</surname><given-names>Shunichi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yakushiji</surname><given-names>Emi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ogura</surname><given-names>Masatsune</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Terao</surname><given-names>Yoshio</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ozasa</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Komatsu</surname><given-names>Tomohiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sotherden</surname><given-names>Grace Megumi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hosoai</surname><given-names>Tamaki</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sakurada</surname><given-names>Masami</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ikewaki</surname><given-names>Katsunori</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Anti-aging and Vascular Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan</aff><aff id="aff2"><label>2</label>Division of Cardiology, Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan</aff><aff id="aff3"><label>3</label>Tokorozawa Heart Center, 2-6-61 Kamiarai, Tokorozawa, Saitama 359-1142, Japan</aff><author-notes><corresp id="cor1">*To whom correspondence should be addressed. E-mail: <email>katsunorike@ndmc.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2014</year></pub-date><volume>55</volume><issue>1</issue><fpage>32</fpage><lpage>39</lpage><history><date date-type="received"><day>2</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>13</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 JCBN</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Reverse cholesterol transport (RCT) is a mechanism critical to the anti-atherogenic property of HDL. Although citrulline contributes to the amelioration of atherosclerosis via endothelial nitric oxide production, it remains unclear whether it affects RCT. This study was undertaken to clarify the effects of citrulline on expressions of specific transporters such as ATP binding cassette transporters (ABC)A1 and ABCG1, and the cholesterol efflux from macrophages to apolipoprotein (apo) A-I or HDL <italic>in vitro</italic> and <italic>ex vivo</italic>. Citrulline increased ABCA1 and ABCG1 mRNA and protein levels in THP-1 macrophages, translating into enhanced apoA-I- and HDL-mediated cholesterol efflux. In the human crossover study, 8 healthy male volunteers (age 30&#x02013;49 years) consumed either 3.2&#x000a0;g/day citrulline or placebo for 1 week. Citrulline consumption brought about significant increases in plasma levels of citrulline and arginine. Supporting the <italic>in vitro</italic> data, monocyte-derived macrophages (MDM) differentiated under autologous post-citrulline sera demonstrated enhancement of both apoA-I- and HDL-mediated cholesterol efflux through increased ABCA1 and ABCG1 expressions, compared to MDM differentiated under pre-citrulline sera. However, the placebo did not modulate these parameters. Therefore, in addition to improving endothelium function, citrulline might have an anti-atherogenic property by increasing RCT of HDL.</p></abstract><kwd-group><kwd>citrulline</kwd><kwd>cholesterol</kwd><kwd>macrophage</kwd><kwd>HDL</kwd><kwd>reverse cholesterol transport</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><p>HDL has been shown to be inversely associated with the risk of atherosclerotic cardiovascular disease (CVD) and is thus considered to be an anti-atherogenic lipoprotein.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>)</sup> However, failure in recent clinical trials with HDL-C raising agents such as nicotinic acid and the cholesteryl ester transfer protein inhibitor torcetrapib to provide cardiovascular benefits despite raising HDL-C levels, indicate that the focus should be on quality (functionality), and not necessarily quantity (HDL-C levels) regarding therapeutic targets.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> Anti-atherogenic functions of HDL include anti-inflammatory,<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup> anti-oxidative,<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup> anti-coagulative,<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> and endothelial-improving functions,<sup>(<xref rid="B7" ref-type="bibr">7</xref>)</sup> as well as enhancement of macrophage reverse cholesterol transport (RCT), a process by which cholesterol is transported from macrophages to the liver for ultimate fecal excretion. Although these functions may comprehensively be involved in the prevention of atherosclerosis progression,<sup>(<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>)</sup> RCT itself has been postulated to play a major role in HDL-mediated atheroprotection.<sup>(<xref rid="B10" ref-type="bibr">10</xref>)</sup> Indeed, quantitative measures of macrophage RCT have been shown to be more strongly associated with atherosclerosis than plasma HDL-C concentrations in mice and humans.<sup>(<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>)</sup> The first critical step of macrophage-derived foam cell RCT involves efflux of cellular cholesterol to circulating HDL particles.</p><p>Research in recent years has documented a specific role for the macrophage transporters ATP-binding cassette subfamilies (ABC) A1 and ABCG1 in cholesterol efflux. ABCA1 has been shown to play an important role in apolipoprotein (apo) A-I-mediated cholesterol efflux from peripheral cells and macrophages while ABCG1 promotes cholesterol efflux from macrophages to HDL particles.<sup>(<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>)</sup> These findings have stimulated efforts to target the macrophage at the cellular level as a means of enhancing overall RCT.</p><p>Endothelial dysfunction is a key feature of early atherosclerotic lesions in both humans and animal models and elevated plasma concentrations of risk factors for CVD.<sup>(<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>)</sup> Citrulline is unusually abundant in watermelon (<italic>Citrullus vulgaris</italic>) and arginine is synthesized from it in endothelial cells.<sup>(<xref rid="B19" ref-type="bibr">19</xref>)</sup> The conversion of citrulline to nitric oxide (NO) via arginine forms part of a recycling pathway.<sup>(<xref rid="B20" ref-type="bibr">20</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>)</sup> NO is synthesized by NO synthase (NOS), which produces citrulline, a precursor of arginine. Chronic consumption of citrulline-rich food has been known to be effective in increasing plasma concentrations of arginine in healthy humans,<sup>(<xref rid="B23" ref-type="bibr">23</xref>)</sup> and Hayashi <italic>et al.</italic><sup>(<xref rid="B24" ref-type="bibr">24</xref>)</sup> reported that citrulline decreased the progression of atherosclerosis in rabbits fed a high cholesterol diet, via endothelial NOS (eNOS). Although citrulline contributes to anti-atherosclerosis via endothelial nitric oxide, it remains unclear whether it affects the anti-atherogenic properties of HDL-mediated RCT functions, or how it might do this. Therefore, the present study was undertaken to investigate the effects of citrulline on ABCA1 and ABCG1 expressions and HDL-mediated cholesterol efflux from macrophages, both <italic>in vitro</italic> and <italic>ex vivo</italic> situations.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Materials</title><p>Actinomysin D (ActD) and human apoA-I were purchased from Sigma (St. Louis, MO). <italic>N</italic><sup>G</sup>-nitro-<sc>l</sc>-arginine methyl ester (L-NAME) and phorbol 12-myristate 13-acetate (PMA) were purchased from Wako Pure Chemical (Tokyo, Japan). HDL was isolated by sequential ultracentrifugation and acetylated LDL (acLDL) was prepared according to the previously reported methods.<sup>(<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>)</sup> L-Citrulline for the <italic>in vitro</italic> and <italic>in vivo</italic> study was purchased from Kanto Chemical CO., INC. (Tokyo, Japan). Placebo and citrulline for the <italic>ex vivo</italic> study were kindly donated by Kyowa Hakko Bio Co., Ltd. (Tokyo, Japan).</p></sec><sec><title>Cell culture</title><p>THP-1 cells (Riken Cell Bank, Tsukuba, Japan) were maintained in RPMI 1640 (Sigma) containing 10% fetal bovine serum (FBS). The differentiation of THP-1 monocytes into macrophages was induced in the presence of 320&#x000a0;nM of PMA for 72&#x000a0;h. RAW264.7 cells (Riken Cell Bank, Tsukuba, Japan) were maintained in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) (Sigma) containing 10% FBS.</p></sec><sec><title>Quantitative real-time PCR</title><p>At the indicated hours after treatment with the compounds, total RNA was extracted from the cells, and first-strand cDNA was synthesized from the total RNA (250&#x000a0;ng) by placing in a Reverse Transcription Reagent (Applied Biosystems, Foster City, CA). Quantitative real-time PCR was performed using an ABI 7900 PCR machine, TaqMan PCR master mix and FAM-labeled TaqMan probes (Assays-on-Demand, Applied Biosystems) for human ABCA1, ABCG1, scavenger receptor class B type I (SR-BI) and 18S ribosomal RNA. The expression data were normalized for 18S levels.</p></sec><sec><title>Western blot analyses</title><p>The cells were harvested and protein extracts prepared as previously described.<sup>(<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B27" ref-type="bibr">27</xref>)</sup> They were then subjected to Western blot analyses (10% SDS-PAGE; 30&#x000a0;&#x000b5;g protein per lane) using rabbit anti-ABCG1 (Novus Biologicals, Littleton, CO) and anti-&#x003b2;-actin (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies. Rat anti-ABCA1 was kindly donated by Dr. S, Yokoyama. The proteins were visualized and quantified using a chemiluminescence method (ECL Pus Western Blotting Detection System; GE Healthcare UK Ltd., Buckinghamshire, UK) and the NIH image analysis software program.</p></sec><sec><title>Determination of cholesterol efflux</title><p>Cholesterol efflux experiments were performed as previously described.<sup>(<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B27" ref-type="bibr">27</xref>)</sup> The cells were labeled with [<sup>3</sup>H] cholesterol (1.0&#x000a0;&#x000b5;Ci/ml) in media containing 0.1% bovine serum albumin (BSA) for 24&#x000a0;h. The cells were washed with phosphate buffered saline (PBS) and incubated in RPMI 1640 containing 0.1% BSA in the presence and absence of apoA-I (10&#x000a0;&#x000b5;g/ml) or HDL (50&#x000a0;&#x000b5;g/ml) for 24&#x000a0;h. The percentage cholesterol efflux was calculated by dividing the media-derived radioactivity by the sum of the radioactivity in the media and the cells.</p></sec><sec><title>Human study</title><p>Eight healthy male volunteers (age 30&#x02013;49 years) were recruited for a crossover study. After an overnight (12&#x000a0;h) fast, the study subjects consumed placebo or 1.6&#x000a0;g citrulline twice daily for 1 week.<sup>(<xref rid="B28" ref-type="bibr">28</xref>)</sup> Blood samples were taken at 0 and 1 week after consumption of placebo or citrulline. All subjects provided written informed consent. The study was approved by the Ethical Committee of the National Defense Medical College.</p></sec><sec><title>Human monocyte isolation and macrophage differentiation</title><p>Human monocytes were isolated as previously described.<sup>(<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B29" ref-type="bibr">29</xref>)</sup> The remaining blood was drawn into heparinized blood collection tubes. Human peripheral blood monocytes were isolated using the method of Fogelman <italic>et al.</italic><sup>(<xref rid="B30" ref-type="bibr">30</xref>)</sup> with Ficoll/Hypaque gradient centrifugation. The mononuclear cells were re-suspended in RPMI 1640 (Sigma) supplemented with 20% autologous serum, plated on to serum-treated 10-cm dishes and incubated for 2&#x000a0;h. Non-adherent cells were removed by washing three times with PBS, and adherent cells were then detached by incubation in PBS containing 10% autologous serum and 0.02% EDTA at 4&#x000b0;C for 30&#x000a0;min. The adherent cells were then washed extensively and re-suspended in RPMI 1640 supplemented with 10% autologous serum. They were then plated on 12-well plates and incubated for 10 days so that they would differentiate into monocyte derived macrophages (MDM). The culture media was changed every 3&#x02013;4 days during this 10-days period.</p></sec><sec><title>Analysis of citrulline and arginine in plasma</title><p>Blood samples were rapidly centrifuged and deproteinized with a 5% (w/v) sulfosalicylic acid solution. The supernatant fractions were stored at &#x02013;80&#x000b0;C for analysis of amino acids. Amino acids were separated and quantified by ion exchange chromatography using an amino acid autoanalyser (Amino Tac, JLC-300; Jeol Ltd, Tokyo, Japan) and the detection sensitivity was 125&#x02013;500&#x000a0;nM. Amino acid analysis was performed using an LC-R-6 column (6.0&#x000a0;&#x000d7;&#x000a0;90&#x000a0;mm I,D., Mitsubishi Chemical Co., Tokyo, Japan). The mobile phase was performed using lithium citrate buffer solution.<sup>(<xref rid="B28" ref-type="bibr">28</xref>)</sup> The autoanalyzer system consisted of the reaction coil (0.25&#x000a0;&#x000d7;&#x000a0;10&#x000a0;m I.D.) and a 570 and 440&#x000a0;nm at 132&#x000b0;C.</p></sec><sec><title>Serum TC, TG, LDL-C, HDL-C, glucose and NO<sub>3</sub></title><p> Serum total cholesterol (TC), triglycerides (TG), LDL-cholesterol (LDL-C) and HDL-C levels were determined by standard enzymatic methods (Measure L, Kyowa Mediceed, Tokyo, Japan). The serum concentration of glucose was determined using an Olympus AU 600 analyser. Blood nitrate (NO<sub>3</sub>) was quantified by the HPLC-UV method.<sup>(<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>)</sup></p></sec><sec><title>Statistical analysis</title><p>Statistical analyses were performed using the Stat View ver. 5.0 software package (SAS Institute Inc., NC). For the cell culture study, two-way factorial ANOVA (Fig.&#x000a0;<xref ref-type="fig" rid="F1">1</xref>A and B) or one-way ANOVA, followed by post-hoc analysis using Bonferroni/Dunn test, with a value of <italic>p</italic>&#x0003c;0.05 considered to be significant. All results were expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Upregulation of ABCA1 and ABCG1 expressions by citrulline</title><p>The effect of citrulline on ABCA1 and ABCG1 mRNA levels in THP-1 macrophages was first investigated. As shown in Fig.&#x000a0;<xref ref-type="fig" rid="F1">1</xref>A and B, 1&#x000a0;mM of citrulline increased ABCA1 and ABCG1 mRNA levels by 74.5&#x000a0;&#x000b1;&#x000a0;21.5% (<italic>p</italic>&#x0003c;0.05) and 58.3&#x000a0;&#x000b1;&#x000a0;22.0% (<italic>p</italic>&#x0003c;0.05), respectively. In contrast, citrulline did not affect SR-BI expression in THP-1 macrophages (data not shown). To further investigate an association between ABCA1 and ABCG1 expressions and NOS, we performed experiments using the NOS inhibitor L-NAME. To our surprise, citrulline-induced ABCA1 and ABCG1 mRNA expression with or without 5&#x000a0;mM of L-NAME in THP-1 macrophages (Fig.&#x000a0;<xref ref-type="fig" rid="F1">1</xref>C and D), indicating that citrulline-induced ABCA1 and ABCG1 expressions were NO-independent. Mirroring the increased mRNA levels, citrulline dose-dependently increased the protein levels of ABCA1 and ABCG1 (Fig.&#x000a0;<xref ref-type="fig" rid="F1">1</xref>E).</p></sec><sec><title>Effect of ABCA1 and ABCG1 mRNA stability by citrulline</title><p>To further explore the mechanisms by which the citrulline increased ABCA1 and ABCG1 mRNA levels in the macrophages, we investigated whether they transcriptionally induced these genes using Act D. As shown in Fig.&#x000a0;<xref ref-type="fig" rid="F2">2</xref>A and B, treatment with 10&#x000a0;&#x000b5;g/ml of ActD did not abolish the inducible effects of citrulline on ABCA1 and ABCG1 expression in THP-1 macrophages. Further, ABCA1 and ABCG1 mRNA decay induced by ActD were inhibited in the presence of the citrulline (Fig.&#x000a0;<xref ref-type="fig" rid="F2">2</xref>C and D), thus indicating they enhanced mRNA stability of ABCA1 by 44.5&#x000a0;&#x000b1;&#x000a0;7.0% (<italic>p</italic>&#x0003c;0.05) and ABCG1 by 39.1&#x000a0;&#x000b1;&#x000a0;5.5% (<italic>p</italic>&#x0003c;0.05). These data indicated that citrulline enhanced mRNA stability of ABCA1 and ABCG1.</p></sec><sec><title>Citrulline enhanced ApoA-I and HDL-mediated cholesterol efflux in THP-1 macrophages</title><p>Next, we investigated the effect of citrulline on cholesterol efflux from THP-1 macrophages mediated by apoA-I or HDL. Citrulline enhanced both apoA-I- and HDL-mediated cholesterol efflux from THP-1 macrophages by 96.1&#x000a0;&#x000b1;&#x000a0;26.1% (<italic>p</italic>&#x0003c;0.05) and 14.4&#x000a0;&#x000b1;&#x000a0;2.5% (<italic>p</italic>&#x0003c;0.05), respectively, compared to control (Fig.&#x000a0;<xref ref-type="fig" rid="F3">3</xref>A and B).</p></sec><sec><title>Citrulline increases serum citrulline and arginine, but has no effects on serum TC, TG, LDL-C, HDL-C, glucose or NO<sub>3</sub></title><p>Our next objective was to clarify the matter of whether the above <italic>in vitro</italic> observations translate into human physiology. As shown in Fig.&#x000a0;<xref ref-type="fig" rid="F4">4</xref>, 1 week of citrulline consumption markedly increased its concentration, by 595% (<italic>p</italic>&#x0003c;0.05). Further, arginine and ornithine, which are metabolically linked with citrulline through the Krebs-Henseleit cycle,<sup>(<xref rid="B33" ref-type="bibr">33</xref>)</sup> were also increased, by 44.7% (<italic>p</italic>&#x0003c;0.05) and 12.4%, respectively. As expected, placebo consumption did not produce any changes. We also found that 1 week of citrulline consumption did not change other parameters, including plasma lipids, glucose, and NO<sub>3</sub> (a metabolite of NO) (data not shown).</p></sec><sec><title>Increased ABCA1 and ABCG1 expression in MDM in presence of post-citrulline sera</title><p>Individual changes in ABCA1 and ABCG1 mRNA levels in the MDM differentiated using autologous sera obtained before and after citrulline or placebo consumption are shown in Fig.&#x000a0;<xref ref-type="fig" rid="F5">5</xref>. Although there was some individual variation, ABCA1 and ABCG1 mRNA levels were increased in the MDM treated with post-citrulline sera as compared to pre-citrulline cells and sera combinations by 95.9% (<italic>p</italic>&#x0003c;0.05) and 162% (<italic>p</italic>&#x0003c;0.05), respectively, in most study subjects. As expected, placebo did not affect the expression of the MDM genes. As shown in Fig.&#x000a0;<xref ref-type="fig" rid="F6">6</xref>, parallel increases in ABCA1 and ABCG1 protein levels were observed. ABCA1 and ABCG1 protein levels in MDM cultured under post-citrulline sera were significantly increased, by 85.7&#x000a0;&#x000b1;&#x000a0;24.1% (<italic>p</italic>&#x0003c;0.05) and 34.7&#x000a0;&#x000b1; 10.5% (<italic>p</italic>&#x0003c;0.05), respectively (Fig.&#x000a0;<xref ref-type="fig" rid="F6">6</xref>C and D). Again, there was no difference between pre- and post-placebo cells and sera (Fig.&#x000a0;<xref ref-type="fig" rid="F6">6</xref>A and B).</p></sec><sec><title>Enhanced ApoA-I and HDL-mediated cholesterol efflux in MDM treated with post-citrulline sera</title><p>Finally, we performed an HDL-mediated cholesterol efflux assay using human MDM cultured in media containing sera obtained before and after citrulline consumption. Consistent with the increased ABCA1/G1 expressions observed above, ApoA-I and HDL-mediated cholesterol effluxes were also significantly increased, by 78.0% (<italic>p</italic>&#x0003c;0.05) and 11.0% (<italic>p</italic>&#x0003c;0.05), respectively, in MDM cultured under post-citrulline sera, as compared to pre-citrulline cells and sera (Fig.&#x000a0;<xref ref-type="fig" rid="F7">7</xref>A and B). Again, no changes were observed for placebo.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>There is a strong inverse correlation between plasma concentrations of HDL-C and risk of atherosclerotic cardiovascular disease.<sup>(<xref rid="B34" ref-type="bibr">34</xref>)</sup> Although the mechanism by which HDL may exert a direct protective effect against the development of atherosclerosis is not yet well understood, it has been postulated that HDL facilitates the efflux of cholesterol from peripheral tissues and transports it back to the liver in a process called RCT.<sup>(<xref rid="B35" ref-type="bibr">35</xref>)</sup> Here we showed, for the first time, that citrulline consumption lead to increased ApoA-I- and HDL-mediated cholesterol efflux from macrophages by inducing ABCA1 and ABCG1 expressions, both in an <italic>in vitro</italic> and <italic>ex vivo</italic> study.</p><p>With regard to mechanisms by which citrulline-mediated induction of ABCA1 and ABCG1 gene expression is transcriptionally regulated, preliminary results showed that citrulline did not increase these promoter activities of well-defined human ABCA1 (&#x02212;940 to +110&#x000a0;bp relative to transcription start site) and ABCG1 (&#x02212;1104 to +38&#x000a0;bp relative to transcription start site in exon 1) or (&#x02212;1180 to +144&#x000a0;bp in exon 5) promoter-luciferase constructs (data not shown).<sup>(<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>)</sup> We then investigated effects of citrulline on mRNA stability of ABCA1 and ABCG1 by using ActD to find that citrulline enhanced ABCA1 and ABCG1 mRNA stability. Indeed, we showed that citrulline enhanced ABCA1 and ABCG1 mRNA stability (Fig.&#x000a0;<xref ref-type="fig" rid="F2">2</xref>C and D), thus resulting in increased steady-state expression of these genes in the macrophage.</p><p>Consistent with the <italic>in vitro</italic> findings, the <italic>ex vivo</italic> human study showed that MDM differentiated under autologous post-citrulline sera enhanced apoA-I- and HDL-mediated cholesterol efflux by increasing ABCA1 and ABCG1 expression without changing plasma HDL-C levels. In theory, since <italic>ex vivo</italic> experiments can provide a situation that is closer to the <italic>in vivo</italic> situation in humans than the <italic>in vitro</italic> setting, comparable results from <italic>in vitro</italic> and <italic>in vivo</italic> studies would provide a reasonable basis for hypothesizing that citrulline promotes RCT by enhancing cholesterol efflux via ABCA1/G1 pathways in humans <italic>in vivo</italic>. This has been highlighted as an important concept in the recent study by Rader <italic>et al.</italic><sup>(<xref rid="B11" ref-type="bibr">11</xref>)</sup> which found that quantitative measures of macrophage RCT are more strongly associated with atherosclerotic disease morbidity than plasma HDL-C concentrations. Enthusiasm concerning cholesterol efflux and its modulation began about 10 years ago when ABCA1 was discovered as the mutation causing human HDL deficiency in Tangier disease. However, although research efforts have been intensely focused on enhancing ABCA1 function, drugs that achieve this are still not available. In the meantime, natural products that enhance cholesterol efflux might be realistic alternatives.</p><p>Several studies have reported an association between citrulline and anti-atherosclerosis. The activation of adhesion molecules elicited by oxidized LDL and the uptake of oxidized LDL by macrophages are key steps in the progression of atherothrombotic cardiovascular diseases.<sup>(<xref rid="B38" ref-type="bibr">38</xref>)</sup> L-citrulline itself is an efficient radical scavenger and is a strong antioxidant.<sup>(<xref rid="B39" ref-type="bibr">39</xref>)</sup> In addition, NO has potent antioxidant properties that exert anti-inflammatory effects and can inhibit LDL oxidation.<sup>(<xref rid="B40" ref-type="bibr">40</xref>)</sup> Recently, Morita <italic>et al.</italic><sup>(<xref rid="B41" ref-type="bibr">41</xref>)</sup> reported that 800&#x000a0;mg/day of L-citrulline intake for 8 weeks reduced serum oxidized LDL and lectin-like oxidized LDL receptor 1 (LOX-1) ligand containing ApoB, an indicator of the biological activity of oxidized lipoprotein binding to LOX-1 in humans with vasospastic angina. NO is a widespread signaling molecule in the cardiovascular system, which functions in multiple ways to protect against the initiation and progression of atherosclerosis.<sup>(<xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>)</sup> Interestingly, in our study, citrulline selectively induced ABCA1 and ABCG1 independently of L-NAME. Also, citrulline consumption did not induce any changes in serum NO<sub>3</sub> levels (data not shown), indicating that citrulline increases HDL-mediated cholesterol efflux from macrophages via an NOS-independent pathway. Thus, overall, our results do not completely exclude the possibility that enhanced cholesterol efflux due to citrulline is NO dependent. We will therefore need to perform an <italic>in vivo</italic> RCT assay using NOS knockout mice as a further study.</p><p>There are several limitations in the present study. First, as mentioned above, the subjects in the human study were healthy volunteers. Therefore, it is difficult to generalize the findings to dyslipidemic patients who are at increased risk for atherosclerosis. Second, 1 week of oral citrulline represents an acute effect, which may differ from the effect of taking it habitually. Third, the present study did not test for the presence of other factors potentially affecting cholesterol efflux nor factors along the pathway by which citrulline consumption could affect NO. Likewise, arginine might increase cholesterol efflux by citrulline administration because citrulline administration increased serum arginine concentration, although arginine concentration is very lower than citrullin concentration. Finally, we did not directly examine whether citrulline actually removed oxidized cholesterol, oxidized fatty acids or oxidized phospholipids from peripheral tissues. Such interesting a posteriori considerations deserve future studies.</p><p>In conclusion, the comparable results from the <italic>in vitro</italic> and <italic>ex vivo</italic> studies indicate that potential anti-atherogenic properties of citrulline could be explained, at least in part, as being due to up-regulated cholesterol efflux from macrophages mediated through ABCA1 and ABCG1 pathways. Combined with its previously-proven endothelial NO-related properties, this favorable effect of citrulline on HDL suggests great synergistic potential with regard to cardioprotective properties.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Fumiko Watanabe of KYOWA HAKKO Bio Co., Ltd., for her helpful assistance. Supported, in part, by a research grant from KYOWA HAKKO Bio Co., Ltd. Placebo and Citrulline for the <italic>ex vivo</italic> study were kindly donated by KYOWA HAKKO Bio Co., Ltd.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>ABCA1</term><def><p>ATP-binding cassette subfamily A member</p></def></def-item><def-item><term>ABCG1</term><def><p>ATP-binding cassette subfamily G member 1</p></def></def-item><def-item><term>acLDL</term><def><p>acetylated LDL</p></def></def-item><def-item><term>ActD</term><def><p>actinomycin D</p></def></def-item><def-item><term>Apo</term><def><p>apolipoprotein</p></def></def-item><def-item><term>BSA</term><def><p>bovine serum albumin</p></def></def-item><def-item><term>cAMP</term><def><p>cyclic AMP</p></def></def-item><def-item><term>CVD</term><def><p>cardiovascular disease</p></def></def-item><def-item><term>eNOS</term><def><p>endothelial nitric oxide synthase</p></def></def-item><def-item><term>L-NAME</term><def><p><italic>N</italic><sup>G</sup>-nitro-<sc>l</sc>-arginine methyl ester</p></def></def-item><def-item><term>LOX-1</term><def><p>lectin-like oxidized LDL receptor 1</p></def></def-item><def-item><term>LXR</term><def><p>liver X receptor</p></def></def-item><def-item><term>MDM</term><def><p>monocyte derived macrophages</p></def></def-item><def-item><term>NO</term><def><p>nitric oxide</p></def></def-item><def-item><term>NO<sub>3</sub></term><def><p>nitrate</p></def></def-item><def-item><term>NOS</term><def><p>nitric oxide synthase</p></def></def-item><def-item><term>PBS</term><def><p>phosphate buffered saline</p></def></def-item><def-item><term>PCR</term><def><p>polymerase chain reaction</p></def></def-item><def-item><term>PMA</term><def><p>phorbol 12-myristate 13-acetate</p></def></def-item><def-item><term>PPAR</term><def><p>peroxisome proliferator-activated receptor</p></def></def-item><def-item><term>RCT</term><def><p>reverse cholesterol transport</p></def></def-item><def-item><term>SR-BI</term><def><p>scavenger receptor class B type I</p></def></def-item><def-item><term>TC</term><def><p>total cholesterol</p></def></def-item><def-item><term>TG</term><def><p>triglycerides</p></def></def-item></def-list></glossary><sec><title>Conflict of Interest</title><p>No potential conflicts of interest were disclosed.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barter</surname><given-names>PJ</given-names></name><name><surname>Caulfield</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of torcetrapib in patients at high risk for coronary events</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>2109</fpage><lpage>2122</lpage><pub-id pub-id-type="pmid">17984165</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Castelli</surname><given-names>WP</given-names></name></person-group><article-title>High density lipoprotein cholesterol and mortality. The Framingham Heart Study</article-title><source>Arteriosclerosis</source><year>1988</year><volume>8</volume><fpage>737</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">3196218</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AIM-HIGH</surname><given-names>Investigators</given-names></name><name><surname>Boden</surname><given-names>WE</given-names></name><name><surname>Probstfield</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><fpage>2255</fpage><lpage>2267</lpage><pub-id pub-id-type="pmid">22085343</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Pritchard</surname><given-names>DK</given-names></name><name><surname>Becker</surname><given-names>L</given-names></name><etal/></person-group><article-title>High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>1919</fpage><lpage>1927</lpage><pub-id pub-id-type="pmid">20974999</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>Barnett</surname><given-names>J</given-names></name><name><surname>Fong</surname><given-names>LG</given-names></name></person-group><article-title>High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein</article-title><source>Biochim Biophys Acta</source><year>1990</year><volume>1044</volume><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">2344447</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>AJ</given-names></name><name><surname>Woollard</surname><given-names>KJ</given-names></name></person-group><article-title>High-density lipoprotein: a potent inhibitor of inflammation</article-title><source>Clin Exp Pharmacol Physiol</source><year>2010</year><volume>37</volume><fpage>710</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">19930423</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorrentino</surname><given-names>SA</given-names></name><name><surname>Besler</surname><given-names>C</given-names></name><name><surname>Rohrer</surname><given-names>L</given-names></name><etal/></person-group><article-title>Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy</article-title><source>Circulation</source><year>2010</year><volume>121</volume><fpage>110</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">20026785</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XP</given-names></name><name><surname>Zhao</surname><given-names>SP</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>QC</given-names></name></person-group><article-title>Protective effect of high density lipoprotein on endothelium-dependent vasodilatation</article-title><source>Int J Cardiol</source><year>2000</year><volume>73</volume><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">10841964</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuvin</surname><given-names>JT</given-names></name><name><surname>Patel</surname><given-names>AR</given-names></name><name><surname>Sidhu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relation between high-density lipoprotein cholesterol and peripheral vasomotor function</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><fpage>275</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">12888130</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuchel</surname><given-names>M</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name></person-group><article-title>Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>2548</fpage><lpage>2555</lpage><pub-id pub-id-type="pmid">16735689</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Alexander</surname><given-names>ET</given-names></name><name><surname>Weibel</surname><given-names>GL</given-names></name><name><surname>Billheimer</surname><given-names>J</given-names></name><name><surname>Rothblat</surname><given-names>GH</given-names></name></person-group><article-title>The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis</article-title><source>J Lipid Res</source><year>2009</year><volume>50 (Suppl)</volume><fpage>S189</fpage><lpage>S194</lpage><pub-id pub-id-type="pmid">19064999</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khera</surname><given-names>AV</given-names></name><name><surname>Cuchel</surname><given-names>M</given-names></name><name><surname>de</surname><given-names>la</given-names></name></person-group><article-title>Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">21226578</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Silver</surname><given-names>DL</given-names></name><name><surname>Thiele</surname><given-names>C</given-names></name><name><surname>Tall</surname><given-names>AR</given-names></name></person-group><article-title>ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>23742</fpage><lpage>23747</lpage><pub-id pub-id-type="pmid">11309399</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Lan</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Matsuura</surname><given-names>F</given-names></name><name><surname>Tall</surname><given-names>AR</given-names></name></person-group><article-title>ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>9774</fpage><lpage>9779</lpage><pub-id pub-id-type="pmid">15210959</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeiher</surname><given-names>AM</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Wollschl&#x000e4;ger</surname><given-names>H</given-names></name><name><surname>Just</surname><given-names>H</given-names></name></person-group><article-title>Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis</article-title><source>Circulation</source><year>1991</year><volume>83</volume><fpage>391</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">1991363</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>F&#x000f6;rstermann</surname><given-names>U</given-names></name><name><surname>M&#x000fc;gge</surname><given-names>A</given-names></name><name><surname>Alheid</surname><given-names>U</given-names></name><name><surname>Haverich</surname><given-names>A</given-names></name><name><surname>Fr&#x000f6;lich</surname><given-names>JC</given-names></name></person-group><article-title>Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries</article-title><source>Circ Res</source><year>1988</year><volume>62</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">2448055</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>R</given-names></name><name><surname>Buse</surname><given-names>J</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name></person-group><article-title>The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>2289</fpage><lpage>2304</lpage><pub-id pub-id-type="pmid">16123508</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marliss</surname><given-names>EB</given-names></name><name><surname>Chevalier</surname><given-names>S</given-names></name><name><surname>Gougeon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">16369774</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimando</surname><given-names>AM</given-names></name><name><surname>Perkins-Veazie</surname><given-names>PM</given-names></name></person-group><article-title>Determination of citrulline in watermelon rind</article-title><source>J Chromatogr A</source><year>2005</year><volume>1078</volume><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">16007998</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Gallagher</surname><given-names>SJ</given-names></name><name><surname>Girerd</surname><given-names>XJ</given-names></name><name><surname>Coleman</surname><given-names>SM</given-names></name><name><surname>Dzau</surname><given-names>VJ</given-names></name><name><surname>Cooke</surname><given-names>JP</given-names></name></person-group><article-title>L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans</article-title><source>J Clin Invest</source><year>1992</year><volume>90</volume><fpage>1248</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">1401062</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Bazer</surname><given-names>FW</given-names></name><name><surname>Cudd</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Pharmacokinetics and safety of arginine supplementation in animals</article-title><source>J Nutr</source><year>2007</year><volume>137</volume><fpage>1673S</fpage><lpage>1680S</lpage><pub-id pub-id-type="pmid">17513446</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangphao</surname><given-names>O</given-names></name><name><surname>Chalon</surname><given-names>S</given-names></name><name><surname>Moreno</surname><given-names>H,</given-names><suffix>Jr</suffix></name><name><surname>Hoffman</surname><given-names>BB</given-names></name><name><surname>Blaschke</surname><given-names>TF</given-names></name></person-group><article-title> Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia</article-title><source>Clin Sci (Lond)</source><year>1999</year><volume>96</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">9918901</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>JK</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Perkins-Veazie</surname><given-names>P</given-names></name><etal/></person-group><article-title>Watermelon consumption increases plasma arginine concentrations in adults</article-title><source>Nutrition</source><year>2007</year><volume>23</volume><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">17352962</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Juliet</surname><given-names>PA</given-names></name><name><surname>Matsui-Hirai</surname><given-names>H</given-names></name><etal/></person-group><article-title>l-Citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>13681</fpage><lpage>13686</lpage><pub-id pub-id-type="pmid">16157883</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayaori</surname><given-names>M</given-names></name><name><surname>Sawada</surname><given-names>S</given-names></name><name><surname>Yonemura</surname><given-names>A</given-names></name><etal/></person-group><article-title>Glucocorticoid receptor regulates ATP-binding cassette transporter-A1 expression and apolipoprotein-mediated cholesterol efflux from macrophages</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2006</year><volume>26</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">16254209</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uto-Kondo</surname><given-names>H</given-names></name><name><surname>Ayaori</surname><given-names>M</given-names></name><name><surname>Ogura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages</article-title><source>Circ Res</source><year>2010</year><volume>106</volume><fpage>779</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">20075335</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakaya</surname><given-names>K</given-names></name><name><surname>Ayaori</surname><given-names>M</given-names></name><name><surname>Hisada</surname><given-names>T</given-names></name><etal/></person-group><article-title>Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma</article-title><source>J Atheroscler Thromb</source><year>2007</year><volume>14</volume><fpage>133</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">17587765</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwedhelm</surname><given-names>E</given-names></name><name><surname>Maas</surname><given-names>R</given-names></name><name><surname>Freese</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism</article-title><source>Br J Clin Pharmacol</source><year>2008</year><volume>65</volume><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">17662090</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Momiyama</surname><given-names>Y</given-names></name><name><surname>Ohmori</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2006</year><volume>26</volume><fpage>e129</fpage><lpage>e130</lpage><pub-id pub-id-type="pmid">16857954</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fogelman</surname><given-names>AM</given-names></name><name><surname>Haberland</surname><given-names>ME</given-names></name><name><surname>Seager</surname><given-names>J</given-names></name><name><surname>Hokom</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>PA</given-names></name></person-group><article-title>Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocyte-macrophages</article-title><source>J Lipid Res</source><year>1981</year><volume>22</volume><fpage>1131</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">6271886</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>LC</given-names></name><name><surname>Wagner</surname><given-names>DA</given-names></name><name><surname>Glogowski</surname><given-names>J</given-names></name><name><surname>Skipper</surname><given-names>PL</given-names></name><name><surname>Wishnok</surname><given-names>JS</given-names></name><name><surname>Tannenbaum</surname><given-names>SR</given-names></name></person-group><article-title>Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids</article-title><source>Anal Biochem</source><year>1982</year><volume>126</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">7181105</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name><name><surname>Nishimura</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Yoshimura</surname><given-names>M</given-names></name></person-group><article-title> Measurements of serum levels of nitrate ions in men and women: implications of endothelium-derived relaxing factor in blood pressure regulation and atherosclerosis</article-title><source>J Cardiovasc Pharmacol</source><year>1992</year><volume>20 (Suppl 12)</volume><fpage>S214</fpage><lpage>S216</lpage><pub-id pub-id-type="pmid">1282974</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsen</surname><given-names>A</given-names></name></person-group><article-title>Proceedings: Krebs-Henseleit urea cycle in cultured human diploid fibroblasts</article-title><source>Arch Int Physiol Biochim</source><year>1975</year><volume>83</volume><fpage>204</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">50817</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>DJ</given-names></name><name><surname>Rifkind</surname><given-names>BM</given-names></name></person-group><article-title>High-density lipoprotein&#x02014;the clinical implications of recent studies</article-title><source>N Engl J Med</source><year>1989</year><volume>321</volume><fpage>1311</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">2677733</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glomset</surname><given-names>JA</given-names></name></person-group><article-title>The plasma lecithins:cholesterol acyltransferase reaction</article-title><source>J Lipid Res</source><year>1968</year><volume>9</volume><fpage>155</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">4868699</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uehara</surname><given-names>Y</given-names></name><name><surname>Miura</surname><given-names>S</given-names></name><name><surname>von Eckardstein</surname><given-names>A</given-names></name><etal/></person-group><article-title>Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element</article-title><source>Atherosclerosis</source><year>2007</year><volume>191</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">16730733</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabol</surname><given-names>SL</given-names></name><name><surname>Brewer</surname><given-names>HB,</given-names><suffix>Jr</suffix></name><name><surname>Santamarina-Fojo</surname><given-names>S</given-names></name></person-group><article-title>The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver</article-title><source>J Lipid Res</source><year>2005</year><volume>46</volume><fpage>2151</fpage><lpage>2167</lpage><pub-id pub-id-type="pmid">16024918</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawamura</surname><given-names>T</given-names></name><name><surname>Kume</surname><given-names>N</given-names></name><name><surname>Aoyama</surname><given-names>T</given-names></name><etal/></person-group><article-title>An endothelial receptor for oxidized low-density lipoprotein</article-title><source>Nature</source><year>1997</year><volume>386</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">9052782</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akashi</surname><given-names>K</given-names></name><name><surname>Miyake</surname><given-names>C</given-names></name><name><surname>Yokota</surname><given-names>A</given-names></name></person-group><article-title>Citrulline, a novel compatible solute in drought-tolerant wild watermelon leaves, is an efficient hydroxyl radical scavenger</article-title><source>FEBS Lett</source><year>2001</year><volume>508</volume><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">11728468</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>C</given-names></name><name><surname>Ackah</surname><given-names>E</given-names></name><name><surname>De</surname><given-names>Nigris</given-names></name></person-group><article-title>Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><fpage>12467</fpage><lpage>12470</lpage><pub-id pub-id-type="pmid">12209007</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Sakurada</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effects of Oral L-Citrulline supplementation on lipoprotein oxidation and endothelial dysfunction in humans with vasospastic angina</article-title><source>Immun Endocr &#x00026; Metab Agents in Med Chem</source><year>2013</year><volume>13</volume><fpage>214</fpage><lpage>220</lpage></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignarro</surname><given-names>LJ</given-names></name><name><surname>Napoli</surname><given-names>C</given-names></name></person-group><article-title>Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis</article-title><source>Curr Atheroscler Rep</source><year>2004</year><volume>6</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">15191702</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>JP</given-names></name></person-group><article-title>Flow, NO, and atherogenesis</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>768</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">12552094</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignarro</surname><given-names>LJ</given-names></name><name><surname>Cirino</surname><given-names>G</given-names></name><name><surname>Casini</surname><given-names>A</given-names></name><name><surname>Napoli</surname><given-names>C</given-names></name></person-group><article-title>Nitric oxide as a signaling molecule in the vascular system: an overview</article-title><source>J Cardiovasc Pharmacol</source><year>1999</year><volume>34</volume><fpage>879</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">10598133</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig.&#x000a0;1</label><caption><p>Citrulline increases expression of ABCA1 and ABCG1 in macrophages. A, B, THP-1 macrophages were treated with control (Cont) or 0.01, 0.1, 1&#x000a0;mM of citrulline (Cit) for 6&#x000a0;h. RNA extraction and quantitative real-time PCR were performed as described in Materials and Methods. The results from 3 separately performed experiments are expressed relative to the vehicles and presented as the mean&#x000a0;&#x000b1;&#x000a0;SEM. Within each treatment<italic/>group, means without a common letter, <italic>p</italic>&#x0003c;0.05. C, D, THP-1 macrophages were treated with Cont or 1&#x000a0;mM of Cit with or without 5&#x000a0;mM of L-NAME for 6&#x000a0;h. The results from 3 separately performed experiments are expressed relative to Cont and presented as the mean&#x000a0;&#x000b1;&#x000a0;SEM. *Different from Cont,<italic> p</italic>&#x0003c;0.05. RNA extraction and quantitative real-time PCR were performed as described in Materials and Methods. E, THP-1 macrophages were lysed and subjected to Western blot analysis 24&#x000a0;h after treatment with Cont or the indicated doses of Cit. The results are from 3 separately performed experiments that yielded similar results.</p></caption><graphic xlink:href="jcbn13-76f01"/></fig><fig id="F2" position="float"><label>Fig.&#x000a0;2</label><caption><p>ABCA1 and ABCG1 mRNA stability enhanced by citrulline in macrophages. A, B, THP-1 macrophages were pretreated with 10&#x000a0;&#x000b5;g/ml of ActD 0.5&#x000a0;h before the treatment with control (Cont) or 1&#x000a0;mM of citrulline (Cit) with or without 10&#x000a0;&#x000b5;g/ml of ActD for 6&#x000a0;h. The results from 3 separately performed experiments are expressed relative to the vehicles and presented as the mean&#x000a0;&#x000b1;&#x000a0;SEM. *Different from Cont or ActD, <italic>p</italic>&#x0003c;0.05, <italic>p</italic>&#x0003c;0.05. RNA extraction and quantitative real-time PCR were performed as described in Materials and Methods. C, D, THP-1 macrophages were pretreated with 10&#x000a0;&#x000b5;g/ml of ActD 0.5&#x000a0;h before the treatment with Cont or 1&#x000a0;mM of Cit with 10&#x000a0;&#x000b5;g/ml of ActD for 1, 3 and 6&#x000a0;h. The results from 3 separately performed experiments are expressed relative to the vehicles and presented as the mean&#x000a0;&#x000b1;&#x000a0;SEM. *Different from Cont,<italic> p</italic>&#x0003c;0.05. RNA extraction and quantitative real-time PCR were performed as described in Materials and Methods.</p></caption><graphic xlink:href="jcbn13-76f02"/></fig><fig id="F3" position="float"><label>Fig.&#x000a0;3</label><caption><p>Citrulline enhances ApoAI- and HDL-mediated cholesterol efflux in macrophages. The indicated doses of citrulline (Cit) or control (Cont) were added to the cultures after [<sup>3</sup>H] cholesterol labeling, which were then incubated in the presence of 10&#x000a0;&#x000b5;g/ml of human apoA-I (A) or 50&#x000a0;&#x000b5;g/ml of HDL (B) for 24&#x000a0;h. Determination of cholesterol efflux from the cells was performed as described in Materials and Methods. The results for 6 samples are presented as the mean&#x000a0;&#x000b1;&#x000a0;SEM. *<italic>p</italic>&#x0003c;0.05 vs Cont.</p></caption><graphic xlink:href="jcbn13-76f03"/></fig><fig id="F4" position="float"><label>Fig.&#x000a0;4</label><caption><p>Citrulline consumption results in increased levels of citrulline/arginine in human plasma. A, plasma was isolated from blood obtained from 8 subjects before and 1 week after consumption of placebo or citrulline. The plasma concentrations of citrulline, arginine and ornithine were determined by amino acid analyzer as described in Materials and Methods. The results are presented as the mean&#x000a0;&#x000b1;&#x000a0;SEM. *Different from 0 week, <italic>p</italic>&#x0003c;0.05.</p></caption><graphic xlink:href="jcbn13-76f04"/></fig><fig id="F5" position="float"><label>Fig.&#x000a0;5</label><caption><p>Citrulline consumption results in increased mRNA levels of ABCA1 and ABCG1 in human monocyte derived macrophages (MDM). The monocytes were cultured and differentiated into macrophages in the presence of autologous sera obtained from 8 subjects before and 1 week after placebo (A, B) or citrulline (C, D) consumption. RNA extraction and quantitative real-time PCR were performed as described in Materials and Methods. The results are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM. *Different from 0 week-citrulline, <italic>p</italic>&#x0003c;0.05.</p></caption><graphic xlink:href="jcbn13-76f05"/></fig><fig id="F6" position="float"><label>Fig.&#x000a0;6</label><caption><p>Citrulline results in increased protein levels of ABCA1 and ABCG1 in human monocyte derived macrophages (MDM). The monocytes were cultured and differentiated into macrophages in the presence of autologous sera obtained from 8 subjects before and 1 week after placebo or citrulline consumption as describe in Materials and Methods. MDM were lysed and subjected to a Western blot analysis. Protein levels were quantified as described in Materials and Methods. Independent experiments from 8 different subjects are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM. *Different from 0 week-citrulline, <italic>p</italic>&#x0003c;0.05.</p></caption><graphic xlink:href="jcbn13-76f06"/></fig><fig id="F7" position="float"><label>Fig.&#x000a0;7</label><caption><p>Citrulline consumption enhances ApoAI- and HDL-mediated cholesterol efflux in human monocyte derived macrophages (MDM). The monocytes were cultured and differentiated into macrophages under pooled sera obtained before and 1 week after placebo or citrulline consumption as described in Materials and Methods. After [<sup>3</sup>H] cholesterol labeling, MDM were incubated in the presence of 10&#x000a0;&#x000b5;g/ml of ApoA-I (A) and 50&#x000a0;&#x000b5;g/ml of HDL (B) for 24&#x000a0;h. Determination of cholesterol efflux from the cells was performed as described in Materials and Methods. The results for HDL-mediated efflux in quadruplicate and ApoA-I-mediated efflux in sextuplicate are presented as the mean&#x000a0;&#x000b1;&#x000a0;SEM. *Different from 0 week-citrulline, <italic>p</italic>&#x0003c;0.05.</p></caption><graphic xlink:href="jcbn13-76f07"/></fig></floats-group></article>